艾德生物(300685.SZ)與強生達成靶向藥物臨牀研究合作
格隆匯3月24日丨艾德生物(300685.SZ)公佈,近日,公司與強生(中國)投資有限公司(以下簡稱“強生”)簽署了合作協議。公司自主研發的“維惠健®”(基於NGS平台的10基因檢測產品,2018年11月20日獲國家藥品監督管理局批准上市),將與強生的靶向藥物在中國臨牀上展開合作,推進維惠健®的變更註冊(擴大其伴隨診斷範圍)。
在腫瘤伴隨診斷領域,公司嚴守國家法律和行業規範,構建了完善的、基於多技術平台的基因檢測整體解決方案。此前,公司ROS1基因融合檢測試劑盒助力輝瑞公司靶向藥物克唑替尼(Xalkori)泛亞太臨牀研究,在日本、韓國、中國台灣獲批上市並納入日本、韓國醫保;2019年6月,“艾惠健?”和“維惠健?”成為禮來RET抑制劑LOXO-292亞洲藥物臨牀試驗的伴隨診斷試劑;2019年11月,公司與日本衞材就其在研膽管癌靶向藥物臨牀上達成合作。此次強生選擇公司作為其腫瘤產品線伴隨診斷合作伙伴是對公司品牌和產品的信任和肯定,對公司未來的發展將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.